Published in Arch Med Res on October 11, 2005
Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. Nat Med (2010) 1.69
Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot Cell (2008) 1.56
Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother (2010) 1.26
Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother (2009) 1.13
The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother (2014) 1.13
Peptide-based Antifungal Therapies against Emerging Infections. Drugs Future (2010) 0.97
Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens. Antimicrob Agents Chemother (2012) 0.97
Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrob Agents Chemother (2006) 0.91
Candidemia in children after complex congenital heart defects surgery treated with caspofungin--our own experience and a review of literature. Med Sci Monit (2011) 0.87
Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans. FEMS Yeast Res (2010) 0.84
Resistance to antifungals that target CYP51. J Chem Biol (2014) 0.81
Silver nanoparticles in dental biomaterials. Int J Biomater (2015) 0.80
S279 point mutations in Candida albicans Sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole. Antimicrob Agents Chemother (2012) 0.77
Candida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells. Curr Fungal Infect Rep (2014) 0.76
Gold Nanoparticle-Photosensitizer Conjugate Based Photodynamic Inactivation of Biofilm Producing Cells: Potential for Treatment of C. albicans Infection in BALB/c Mice. PLoS One (2015) 0.76
Diagnosis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-2). Turk J Haematol (2014) 0.75
Transcriptional Control of Drug Resistance, Virulence and Immune System Evasion in Pathogenic Fungi: A Cross-Species Comparison. Front Cell Infect Microbiol (2016) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis (2007) 4.23
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med (2008) 3.36
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother (2002) 2.76
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis (2012) 2.26
In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother (2002) 2.03
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother (2007) 1.77
Antifungal prophylaxis in the intensive care unit: who should get it? Crit Care Med (2006) 1.72
Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother (2003) 1.64
In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother (2004) 1.55
In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother (2002) 1.52
Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis (2002) 1.47
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother (2002) 1.27
Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol (2010) 1.24
Ocular manifestations of candidemia. Clin Infect Dis (2011) 1.22
Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. Diagn Microbiol Infect Dis (2003) 1.15
Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol (2006) 1.14
The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov (2012) 1.13
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol (2006) 1.10
Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J Clin Microbiol (2012) 1.10
Deeply invasive candidiasis. Infect Dis Clin North Am (2002) 1.08
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother (2005) 1.06
Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) (2003) 1.04
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother (2006) 1.01
What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med (2014) 1.01
Comparison of PCR- and HinfI restriction endonuclease-based methods for typing of Candida krusei isolates. J Clin Microbiol (2004) 1.00
Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents (2004) 0.97
Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis (2013) 0.96
Evaluation of a method for identification of Candida dubliniensis bloodstream isolates. J Clin Microbiol (2003) 0.96
The value of single-pathogen antibacterial agents. Nat Rev Drug Discov (2013) 0.95
A web-based endpoint adjudication system for interim analyses in clinical trials. Clin Trials (2009) 0.93
Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother (2011) 0.93
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother (2008) 0.92
New agents for the treatment of systemic fungal infections--current status. Expert Opin Emerg Drugs (2002) 0.91
Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. Arch Med Res (2006) 0.91
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care (2009) 0.91
Current options in antifungal pharmacotherapy. Pharmacotherapy (2008) 0.90
Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care (2010) 0.90
In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol (2002) 0.90
All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis (2002) 0.87
Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit. Surg Infect (Larchmt) (2005) 0.87
Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis (2002) 0.86
Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother (2008) 0.85
Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother (2004) 0.85
Risk factors for hyperglycemia in hospitalized adults receiving gatifloxacin: a retrospective, nested case-controlled analysis. Clin Ther (2008) 0.84
Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis. J Clin Microbiol (2005) 0.84
Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer (2005) 0.84
Ventilator-associated pneumonia: a review. Hosp Pract (1995) (2012) 0.84
Ravuconazole Eisai/Bristol-Myers Squibb. Curr Opin Investig Drugs (2002) 0.83
Tigecycline : a critical safety review. Expert Opin Drug Saf (2014) 0.81
Galactomannan and the diagnosis of invasive aspergillosis. Clin Infect Dis (2006) 0.80
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis (2004) 0.80
Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis (2005) 0.80
Therapy of common superficial fungal infections. Dermatol Ther (2004) 0.80
Disk diffusion-based methods for determining Candida parapsilosis susceptibility to anidulafungin. Antimicrob Agents Chemother (2003) 0.79
Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? Crit Care Med (2004) 0.79
Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolates. J Clin Microbiol (2004) 0.78
Candida in the peritoneum: passenger or pathogen? Crit Care Med (2006) 0.78
Infections of cardiac implantable electronic devices: a retrospective multicenter observational study. Medicine (Baltimore) (2012) 0.77
Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother (2002) 0.77
Lack of correlation of 24- vs. 48-h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis. Mycoses (2009) 0.76
Systemic antifungal therapy in patients without documented invasive fungal infection: a peek into the world of empirical antifungal therapy*. Crit Care Med (2012) 0.76
Invasive mycoses: evolving challenges and opportunities in antifungal therapy (multimedia activity). Am J Med (2011) 0.76
Prophylaxis for invasive candidiasis in the intensive care unit: is it time? Crit Care Med (2005) 0.75
Reply to "Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!". J Clin Microbiol (2013) 0.75
Reply to Chow and Hurley. Clin Infect Dis (2012) 0.75